Myositis Diagnosis and Management
Authors:
- Guillaume ChevrelGCGuillaume Chevrel
- Reinhard HohlfeldRHReinhard Hohlfeld
Open Access
- 1 February 2002
- journal article
- Published by BMJ in Practical Neurology
- Vol. 2 (1) , 4-11
Abstract
INTRODUCTION The inflammatory myopathies comprise a group of acquired myopathies in which muscle weakness and inflammatory infiltrates are the principal clinical and histological findings. Traditionally, a distinction is made between polymyositis, dermatomyositis and inclusion body myositis. This brief review will focus on polymyositis. CLINICAL FEATURES Diagnostic criteria Polymyositis is characterized by symmetrical proximal muscle weakness. Respiratory, pharyngeal and neck muscles may also be involved during later stages of the disease (Dalakas & Sivakumar 1996; Mantegazza et al. 1997; Dalakas 1998a). Up to half the patients suffer from muscle pain or arthralgia. The history, clinical symptoms and signs, elevated serum levels of muscle enzymes, electrophysiological changes and histological findings together provide the basis for the diagnosis. The main diagnostic criteria and features are summarized in Table 1 for polymyositis and for the two other forms of idiopathic inflammatory myopathies, dermatomyositis, and inclusion body myositis. Clinically, poylmyositis and dermatomyositis are distinguished byKeywords
This publication has 28 references indexed in Scilit:
- Muscle BiopsyPractical Neurology, 2001
- Intravenous Immunoglobulin – How to use itPractical Neurology, 2001
- Autoantibody profiles in the sera of European patients with myositisAnnals of the Rheumatic Diseases, 2001
- Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathiesArthritis & Rheumatism, 1997
- The use of intravenous immunoglobulins in the treatment of neuromuscular disordersCurrent Opinion in Neurology, 1996
- Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis.Journal of Clinical Investigation, 1996
- The immunopathologic and inflammatory differences between dermatomyositis, polymyositis and sporadic inclusion body myositisCurrent Opinion in Neurology, 1996
- MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathiesClinical and Experimental Immunology, 1994
- A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for DermatomyositisNew England Journal of Medicine, 1993
- Polymyositis Mediated by T Lymphocytes That Express the γ/δ ReceptorNew England Journal of Medicine, 1991